Longeveron (LGVN) Non Operating Income (2022 - 2026)
Longeveron (LGVN) posted quarterly Non Operating Income of $39000.0 for Q1 2026, down 77.06% year-over-year from $170000.0 in Q1 2025, and up 186.67% quarter-over-quarter from -$45000.0 in Q4 2025.
Longeveron (LGVN) Non Operating Income (2022 - 2026) Analysis & Trends
Longeveron's Non Operating Income history runs 5 years deep, the most recent figure standing at $39000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 77.06% year-over-year to $39000.0; the TTM figure through Mar 2026 stood at $452000.0 (down 34.21% YoY), while the FY2025 annual figure was $583000.0, up 6.19% from the prior year.
- Non Operating Income for Q1 2026 stood at $39000.0, up from -$45000.0 in the prior quarter.
- The five-year high for Non Operating Income was $606000.0 in Q4 2022, with the low at -$1.4 million in Q2 2022.
- The 5-year median for Non Operating Income is $80000.0 (2023), against an average of -$333.33.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income tumbled 197.03% in 2023, then surged 431.25% in 2025.
- Longeveron's Non Operating Income stood at $606000.0 in 2022, then sank by 197.03% to -$588000.0 in 2023, then soared by 134.01% to $200000.0 in 2024, then slumped by 122.5% to -$45000.0 in 2025, then surged by 186.67% to $39000.0 in 2026.
- Business Quant data shows LGVN's Non Operating Income at $39000.0 in Q1 2026, -$45000.0 in Q4 2025, and $89000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 98,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98,000.00 |
| Mar 31, 2026 | 39,000.00 |
| Dec 31, 2025 | -45,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 369,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Sep 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | -588,000.00 |
| Sep 30, 2023 | 55,000.00 |
| Jun 30, 2023 | 80,000.00 |
| Mar 31, 2023 | 69,000.00 |
| Dec 31, 2022 | 606,000.00 |
| Jun 30, 2022 | -1.40 Mn |